Nammuang, do you expect investors to talk about ATRS everyday on this board? Post something about ATRS & investors will respond.
I think its a different formulation of Testosterone enanthate & not a different injector. If more injection site reactions had occurred then maybe they could have used this as a bridging study.
What would happen with the TEVA/ATRS epipen partnership on a buyout. ATRS could get the shaft unless something is in the partnership agreement.
I'm not sure but its not uncommon for IPO's to have several lockup dates. I got the info off twitter from a respected poster.
I'm not sure if this is a buying opportunity but I've reduced my exposure significantly.
Out of the hundreds of biotechs out there Cramer bashed a stock which is trading down for the year & has a Analyst and Investor Day presentation in a few days. Why not bash a stock which is trading up 100% if its a biotech bubble?
I hate to burst your bubble.
TEVA acquired the drug from Labry Biologics in 2014 which was 10 yrs after the partnering agreement so there is no way Pen 1 has anything to do with this drug.
Mo, I like the companies technology. Its also pretty clear that the stocks been beaten down to unreasonable levels by the warrant holders.
Its one of those stocks which can explode higher without warning if a hedge decides to take a big position or just linger at these levels for years.
Roche is working with PRTA for those who don't know this.
"But few of those antibodies will be able to penetrate the shield of tightly packed cells known as the blood–brain barrier, which protects the brain from blood-borne intruders such as bacteria, but also keeps out most large drug molecules. Antibody concentrations in the brain are typically about a thousand times lower than in the blood, says Watts.
In two papers published today in Science Translational Medicine1,2, Watts and his collaborators report the design of an antibody that surmounts this obstacle.
The antibody targets two proteins. The first, called β-secretase 1, is a popular target for drugs to treat Alzheimer's disease, because it has an important role in the production of amyloid peptides in the brain. According to the 'amyloid hypothesis', amyloid aggregates are responsible for the hallmark brain damage and memory loss of the condition. "
Google this article
"Engineered antibodies cross blood–brain barrier -Technique could be used to design therapies for Alzheimer's and other diseases."
The spring is getting ready to blowup.